Savara (SVRA) Receivables - Other (2010 - 2016)
Savara (SVRA) reported Receivables - Other of $400000.0 for Q4 2016, up 1270.57% quarter-over-quarter from $29185.0 in Q3 2013.
Savara (SVRA) Receivables - Other (2010 - 2016) Analysis & Trends
Savara (SVRA) has 5 years of Receivables - Other data on file, last reported at $400000.0 in Q4 2016.
- Receivables - Other for Q4 2016 came in at $400000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $400000.0 (changed N/A YoY), and the FY2016 annual result was $400000.0, changed N/A from the prior year.
- Receivables - Other rose to $400000.0 in Q4 2016 per SVRA's latest filing, from $29185.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $400000.0 in Q4 2016 and troughed at $9659.0 in Q2 2013.
- A 3-year average of $64002.8 and a median of $15316.0 in 2012 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2012 and 2013: Receivables - Other surged 7849.45% in 2012, then plunged 55.16% in 2013.
- A 3-year view of Receivables - Other shows it stood at $15689.0 in 2012, then surged by 86.02% to $29185.0 in 2013, then jumped by 1270.57% to $400000.0 in 2016.
- Business Quant data shows SVRA's Receivables - Other at $400000.0 in Q4 2016, $29185.0 in Q3 2013, and $9659.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 400,000.00 |
| Dec 31, 2016 | 400,000.00 |
| Sep 30, 2013 | 29,185.00 |
| Sep 30, 2013 | 29,185.00 |
| Jun 30, 2013 | 9,659.00 |
| Jun 30, 2013 | 9,659.00 |
| Mar 31, 2013 | 10,831.00 |
| Mar 31, 2013 | 10,831.00 |
| Dec 31, 2012 | 15,689.00 |
| Dec 31, 2012 | 15,689.00 |
| Sep 30, 2012 | 10,172.00 |
| Sep 30, 2012 | 10,172.00 |
| Jun 30, 2012 | 21,543.00 |
| Jun 30, 2012 | 21,543.00 |
| Mar 31, 2012 | 14,943.00 |
| Mar 31, 2012 | 14,943.00 |
| Dec 31, 2011 | 17,245.00 |
| Dec 31, 2011 | 17,245.00 |
| Sep 30, 2011 | 6,869.00 |
| Sep 30, 2011 | 6,869.00 |